Progression-free survival (PFS), the time from registration or randomisation of a patient until objective disease progression or death, can be considered as an outcome for clinical research and also as a basis for regulatory approval. Current experience suggests that greater standardisation and consistency are needed for clinical trials utilising PFS endpoints. To this end, the Biotherapy Development Association (BDA) convened a breakout session on the topic of PFS during its Third Alpine Meeting held 14–16 March 2007. Representatives of the pharmaceutical industry, regulatory agencies, academia, and patient advocacy groups identified challenges, developed recommendations, and worked to build consensus regarding the conduct of clinical trials utilising PFS as an end-point to help speed new targeted biologics to the patient bedside.
|Data di pubblicazione:||2007|
|Titolo:||“Progression-free survival as an end-point in clinical trials of biotherapeutic agents”|
|Autori:||LOTHAR BERGMANN; STEVEN HIRSCHFELD; CHARLES MORRIS; PALMERI S; ANDREW STONE; BIOTHERAPY DEVELOPMENT; ASSOCIATION BDA|
|Tipologia:||Articolo su rivista|
|Citazione:||LOTHAR BERGMANN, STEVEN HIRSCHFELD, CHARLES MORRIS, PALMERI S, ANDREW STONE, BIOTHERAPY DEVELOPMENT, et al. (2007). “Progression-free survival as an end-point in clinical trials of biotherapeutic agents”. EUROPEAN JOURNAL OF CANCER, n.9, 23-28.|
|Digital Object Identifier (DOI):||10.1016/j.ejcsup.2007.09.002|
|Appare nelle tipologie:||01 - Articolo su rivista|